Ranbaxy Laboratories, Inc.

Sun Pharmaceutical Industries Limited

Mahavir Singh Khanna

Mohan Prasad

Yatendra Kumar

Rajesh Kumar Thaper

Anu Mittal

Hari Babu Matta

Anmol Kumar Ray

Naresh Kumar

Jag Mohan Khanna

Ram Thaimattam

Neela Praveen Kumar

Brij Khera

Bakthavathsalan Vijayaraghavan

Bhavin Prabhudas Thanki

Anil Saini

Kapil Sharma

Rakesh Singh

Nagaraju Gottumukkala

Gopal Singh Bisht

The present invention provides processes for the preparation of ibrutinib, intermediate compounds of Formula VI and Formula VIII, and salts thereof. The processes of the present invention are commercially viable, cost-effective, environmentally friendly, and make use of inexpensive, non-hazardous, safe chemicals that are easy to handle.

Process for the preparation of ibrutinib

The present invention relates to a stable amorphous ticagrelor and a process for its preparation.

Stable amorphous ticagrelor and a process for its preparation

The present invention relates to pure crystalline Form II of an L-malic acid salt of sunitinib and a process for its preparation. The invention further provides crystalline Form II of an L-malic acid salt of sunitinib having a purity of at least 97.0%. The invention also provides crystalline Form II of an L-malic acid salt of sunitinib substantially free of an anti-oxidant. The invention also provides crystalline Form II of L-malic acid salt of sunitinib which remains chemically pure on storage at 25&#xb0; C.&#xb1;2&#xb0; C. and 40&#xb0; C.&#xb1;2&#xb0; C. at a relative humidity of 60%&#xb1;5% and 75%&#xb1;5%, respectively, for at least 1 month.

Pure crystalline Form II of L-malic acid salt of sunitinib and processes for its preparation

The present invention relates to an ascorbic acid salt of sunitinib and a process for its preparation. The present invention further provides a crystalline Form I of an L-ascorbic acid salt of sunitinib.

Ascorbic acid salt of sunitinib

The present invention relates to the salts of dexlansoprazole in amorphous form. The present invention further relates to processes for the preparation of salts of dexlansoprazole.

Salts of dexlansoprazole and their preparation

The present invention relates to a process for the preparation of crystalline dexlansoprazole.

Process for the preparation of dexlansoprazole

The present invention relates to crystalline forms of bosentan salts and processes for their preparation.(FORMULA) 

Crystalline forms of bosentan salts and processes for their preparation

The invention relates to crystalline barium salt of (S)-omeprazole, which is (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole. The invention also relates to processes for preparing crystalline barium salt of (S)-omeprazole and pharmaceutical compositions that include the crystalline barium salt of (S)-omeprazole so prepared.

Barium salt of benzimidazole derivative

The invention relates to crystalline barium salt of (S)-omeprazole, which is (S)--methoxy--[[(-methoxy--dimethyl--pyridinyl)-methyl]sulfinyl]-H-benzimidazole. The invention also relates to processes for preparing crystalline barium salt of (S)-omeprazole and pharmaceutical compositions that include the crystalline barium salt of (S)-omeprazole so prepared.

The present invention relates to a process for enantioselective synthesis of substituted pyridinylmethyl sulfinyl-benzimidazole of compound of Formula (I). The process includes enantioselective catalytic oxidation of a substituted pyridinylmethyl prochiral sulfide derivative of compound of Formula (II) with an oxidizing agent in the presence of a chiral transition metal complex and a base in the absence of an organic solvent. 

Processes for the preparation of substituted sulfoxides

The invention relates to an amorphous form of the salts of the (-) enantiomer or (S)-enantiomer of omeprazole, i.e., esomeprazole. The invention also relates to processes for preparing amorphous esomeprazole salts and pharmaceutical compositions that include the amorphous esomeprazole salts.

Amorphous form of esomeprazole salts

A process for the manufacture of Form 1 ranitidine hydrochloride (N-[2-[[[5-(Dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl-N'-methyl-2- nitro-1,1-ethenediamine) hydrochloride, is described. A process to convert ranitidine hydrochloride Form 2 to Form 1 is also described.

Growing community of inventors

New Delhi, India

Mahavir Singh Khanna